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 Highlights 
 
 We reviewed the  literature of structural imaging changes in preclinical dementia. 
 There was a high overlap of brain regions implicated in both preclinical and sporadic AD. 
 The imaging literature in relation to AD risk factors was highly discrepant. 
 More research and validation studies of structural imaging techniques are needed. 
  
 ABSTRACT 
The last decade has witnessed a proliferation of neuroimaging studies characterising brain 
changes associated with Alzheimer‟s disease (AD), where both widespread atrophy and 
„signature‟ brain regions have been implicated. In parallel, a prolonged latency period has been 
established in AD, with abnormal cerebral changes beginning many years before symptom onset. 
This raises the possibility of early therapeutic intervention, even before symptoms, when 
treatments could have the greatest effect on disease-course modification. Two important 
prerequisites of this endeavour are (1) accurate characterisation or risk stratification and (2) 
monitoring of progression using neuroimaging outcomes as a surrogate biomarker in those 
without symptoms but who will develop AD, here referred to as preclinical AD. Structural 
neuroimaging modalities have been used to identify brain changes related to risk factors for AD, 
such as familial genetic mutations, risk genes (for example apolipoprotein epsilon-4 allele), 
and/or family history. In this review, we summarise structural imaging findings in preclinical 
AD. Overall, the literature suggests early vulnerability in characteristic regions, such as the 
medial temporal lobe structures and the precuneus, as well as white matter tracts in the fornix, 
cingulum and corpus callosum. We conclude that while structural markers are promising, more 
research and validation studies are needed before future secondary prevention trials can adopt 
structural imaging biomarkers as either stratification or surrogate biomarkers. 
 
Search terms: Alzheimer's disease, neurodegeneration, preclinical dementia, magnetic 
resonance imaging, diffusion weighted imaging, neuroimaging, cognitive impairment 
 
  
1. INTRODUCTION 
 
There are now 30 million people living with dementia, and the number is expected to rise to 115 
million in 2050 (World Alzheimer Report 2010, www.alz.org). Current treatments are 
symptomatic and limited to Alzheimer‟s disease (AD). It is assumed that functional decline and 
dementia will be a relatively late feature in the pathophysiology of AD, with increasing evidence 
of an insidious latency period, with pathological changes beginning decades before symptom 
onset (Trojanowski et al., 2010). The „amyloid cascade hypothesis‟ posits an initiating event of 
amyloidosis, with subsequent tau pathology and other downstream processes involving 
neurotoxicity and progressive cerebral atrophy (Hardy and Selkoe, 2002). This self-perpetuating 
mechanism of neurodegeneration is difficult to slow once established, and may partly account for 
the spate of notable clinical trial failures, particularly anti-amyloid therapy (Doody et al., 2014). 
Thus, recent proposals are urging the need to shift the focus to presymptomatic interventional 
trials in individuals at elevated risk for AD (Caselli and Reiman, 2013; Ritchie et al., 2015). 
 
To facilitate this endeavour, biomarkers are mandatory prerequisites (a) to aid in the early pre-
symptomatic detection of AD for recruitment to clinical trials and (b) to serve as surrogate 
markers for disease progression and to be used therein as intermediary phenotypes to assess the 
efficacy of potential disease-modifying treatments. In clinical trials of presymptomatic dementia, 
any disease-related changes would likely be subtle and therein lays the challenge of establishing 
the means to assess outcomes in clinical trials. Ideally, a biomarker should sensitively and 
specifically reflect the underlying pathology (i.e. amyloid / tau deposition, grey matter volume 
loss, etc.), be easily reproducible and accessible (i.e. available in standard clinical settings), and 
be non-invasive. In this regard, structural neuroimaging techniques – T1-MRI and diffusion 
weighted imaging (DTI) – that enable assessment of grey matter volume loss, cortical thinning, 
or white matter microstructural changes have contributed to the characterisation of disease-
related changes in neurodegenerative conditions, such as AD (Braskie and Thompson, 2014), 
dementia with Lewy bodies (Mak et al., 2014a), and Parkinson‟s disease (Mak et al., 2015a). 
Similarly, evidence from structural neuroimaging studies have begun to reveal characteristic 
patterns of grey matter atrophy and white matter abnormalities in preclinical dementia, 
particularly involving individuals possessing (a) familial AD (FAD) genetic mutations 
(Ginestroni et al., 2009; Li et al., 2015; Quiroz et al., 2013; Reiman et al., 2012; Ridha et al., 
2006; Ringman et al., 2007; Schott et al., 2003; Thordardottir et al., 2015), (b) one or two copies 
of the apolipoprotein epsilon-4 allele (ApoE4) (Burggren et al., 2008; Cherbuin et al., 2008; den 
Heijer et al., 2002; Desikan et al., 2013; Fan et al., 2010; Hashimoto et al., 2009; Lemaître et al., 
2005; Shaw et al., 2007; Smith et al., 2010; Wishart et al., 2006), (c) a family history of AD
 
(Berti et al., 2011; Fox et al., 1999; Honea et al., 2011, 2010; Mosconi et al., 2014). 
 
The purpose of this review is to provide an exhaustive summary of the literature concerning grey 
and white matter abnormalities in presymptomatic individuals at high-risk of dementia: 
individuals with familial AD genetic mutations, carriers of ApoE4 and those with a positive 
family history of dementia. We first begin with a brief description of each risk factor before 
reviewing the literature of structural neuroimaging in preclinical AD: (a) macroscopic grey 
matter atrophy and cortical thinning, (b) hippocampal and other subcortical atrophy, (c) 
microstructural properties as measured by DTI, and (d) macroscale changes in the connectome.  
The potential influence of age on some of these risk factors will be discussed. Lastly, we 
conclude with future directions and provide a summary of structural neuroimaging in preclinical 
AD. 
 
2. RISK FACTORS IN ALZHEIMER’S DISEASE  
Genetic mutations 
FAD is a rare and inheritable form of AD and it is typically associated with an early onset before 
the age of 65 (Ringman, 2005). Causative factors of FAD include autosomal-dominant 
inheritable mutations in the genes of presenilin 1 (PSEN1), presenilin 2 (PSEN2) and amyloid 
precursor protein (APP). Their effects are fully penetrant, implying a near certainty of 
developing AD in carriers, often at an earlier age (~ 30 – 50 years) as well as exhibiting a more 
aggressive disease course and shorter relative survival time compared to typical AD (Rossor et 
al., 2010; Seltzer, 2016).  
 
Although FAD only accounts for 1% of all AD cases, presymptomatic FAD mutation carriers 
offer an opportunity to investigate the earliest clinical and biomarker substrates of the prodromal 
dementia stage. For instance, it is possible to estimate the age of onset in FAD mutation carriers, 
allowing enrolment into therapeutic trials years and even decades before the emergence of 
cognitive decline.  Because the clinical (i.e. insidious onset of amnestic symptoms and 
progression of decline in multiple cognitive domains) and pathological features (i.e. neuronal 
loss, amyloid plaques and neurofibrillary tangles) of FAD are similar to sporadic AD, putative 
drugs that demonstrate high efficacy in the prevention or delay of dementia in FAD trials are 
likely to inform other disease modification trials in sporadic AD. The notion for FAD as a model 
to investigate the pathogenesis of sporadic AD has also received support from spatial 
overlapping of brain regions that are commonly implicated in sporadic AD (will be discussed in 
more detail later). 
 
Apolipoprotein epsilon-4  
While autosomal dominant mutations exist in AD, they are exceedingly rare as the majority of 
AD cases most likely involve a multifaceted interplay of genetic and environmental risk factors. 
Investigating the imaging characteristics of genotypes offers another opportunity to investigate 
morphological aberrations in the brain during preclinical AD. The ApoE gene exists as three 
polymorphic alleles – E2, E3, and E4 – which have a worldwide frequency of 8.4%, 77.9% and 
13.7% respectively (Farrer, 1997). Inheritance of ApoE4 is established as the greatest genetic 
risk factor associated with AD with dose-dependent effects (Harold et al., 2009). The 
mechanisms by which ApoE4 influences the risk, onset and progression of neurodegeneration 
have been the subject of intense research (Farrer, 1997), revealing a range of influences 
including beta-amyloid metabolism, impaired clearance of beta-amyloid across the blood brain 
barrier, and increased oligomerization of beta-amyloid in the brain (Liu et al., 2013).  
 
Family history 
AD is highly heritable. Even in those without FAD, a family history of dementia is another 
significant risk factor for AD particularly of the late-onset type (LOAD). The risk for developing 
LOAD is 4-10 fold higher in first-degree relatives of LOAD patients, and is highest in children 
of parents affected by LOAD (Farrer, 1997; Fratiglioni et al., 1993). However, its association 
with AD appears to be less certain compared to FAD mutations and ApoE4 carriage, as several 
studies have not reported an association between family history of dementia and elevated risk of 
AD (Lindsay et al., 2002; Tyas et al., 2001). The link between family history and AD is most 
likely mediated at least in part by ApoE4 carriage. A 6-year follow-up study in the Kungsholmen 
Project Cohort showed that family history of dementia conferred an increased risk of dementia 
only among ApoE4 carriers (Huang et al., 2004). This finding has been corroborated by other 
evidence showing an additive effect of both ApoE4 and family history on of age of onset and 
cognitive decline (Duara et al., 1996; Hayden et al., 2010; Jarvik et al., 1996). There is also 
evidence from imaging (will be discussed in greater detail) and CSF studies suggesting a 
stronger maternal contribution to dementia compared to paternal dementia (Edland et al., 1996; 
Honea et al., 2012). In light of these findings, others have implicated the mitochondrial DNA in 
the genetic transmission of AD (Mosconi et al., 2011; Swerdlow et al., 2010). 
 
Translocase of outer mitochondrial membrane 40 
In light of previous evidence showing a stronger AD risk from maternal dementia, others have 
implicated the mitochondrial DNA in the genetic transmission and pathogenesis of AD (Mosconi 
et al., 2011; Swerdlow et al., 2010). Accordingly, the translocase of outer mitochondrial 
membrane 40 (TOMM40) has emerged as a potential candidate gene for AD. Variable poly-T 
length polymorphism at rs10524523, within intron 6 of TOMM40 gene, has been shown to 
influence the risk and age of onset in AD (Roses et al., 2010). Specifically, the long allele was 
associated with a 7-year earlier age of onset of AD in a relatively small sample of ApoE4 
heterozygotes. However, these findings have not been consistently replicated in substantially 
larger samples (Cruchaga et al., 2011; Jun et al., 2012), and the influence of the TOMM40 gene 
in preclinical AD remains unclear. 
 
Brain derived neurotrophic factor 
Finally, some of the remaining variance in dementia risk could be accounted for by 
neurotrophins as they are influenced by a myriad of factors including caloric intake (Araya et al., 
2008) and physical activity (Neeper et al., 1995). The brain-derived neurotrophic factor (BDNF) 
is essential for neuronal survival and synaptic function, particularly in the hippocampus (Tapia-
Arancibia et al., 2008). Histopathological and CSF studies have consistently documented 
reductions in BDNF expression among AD patients (Laske et al., 2007; Phillips et al., 1991), as 
well as correlations with episodic memory and progression from MCI to AD (Forlenza et al., 
2015). 
 
3. METHODS 
Literature searches were performed to review structural brain changes in preclinical dementia. 
Two reviewers (EM and SG) searched PubMed for articles published from Jan 1990 till present. 
We identified relevant papers using the keywords: 'structural magnetic resonance imaging', 
'diffusion tensor imaging', 'Alzheimer‟s disease'. Further, we searched for „amyloid, 'family 
history', 'ApoE4', 'PSEN' and 'APP'. Articles included were only human studies in the English 
language. Studies were considered for inclusion if structural neuroimaging modalities (T1 MRI 
and diffusion-weighted MRI) were used to investigate brain changes related to risk factors of 
AD, such as familial APP/PSEN gene mutations, the presence of ApoE4 and/or family history of 
AD. No further attempts were made to extract quantitative data for meta-analysis. 
 
4. RESULTS 
This database search resulted in 606 studies. Full-text articles were obtained to assess further 
eligibility, resulting in the exclusion of articles based on methodological consideration or sample 
characteristics, and the inclusion of additional studies from the references of these individual 
articles. After detailed evaluation, 95 key papers published between 1996 and 2016 were 
included in the systematic review.  A summary of principal findings from highlighted studies 
(i.e. large cohort studies with longitudinal follow-up) is described in Table 1 and 2. 
 
5. CORTICAL GREY MATTER CHANGES 
In general, structural imaging studies across preclinical groups have converged to reveal an 
atrophic cortical pattern that is characteristic of AD (Quiroz et al., 2013), such as increased 
longitudinal whole brain atrophy rates (Chen et al., 2007; Fox et al., 1999; Ridha et al., 2008; 
Schott et al., 2010), parahippocampal atrophy (Hashimoto et al., 2009), and atrophy / cortical 
thinning in frontal, temporal and parietal cortices as well as the precuneus (Berti et al., 2011; 
Burggren et al., 2008; Chen et al., 2007; Ginestroni et al., 2009; Mosconi et al., 2014; Schott et 
al., 2003). It is noteworthy that atrophy or cortical thinning in temporo-parietal cortices has been 
consistently predictive of conversion from mild cognitive impairment (MCI) to AD in 
longitudinal studies (Chételat et al., 2005; Risacher et al., 2010), while the precuneus has also 
been shown to be an early site of preferential amyloid uptake in positron emission tomography 
(PET) studies (Villemagne et al., 2009), supporting the notion that these cortical changes are 
potential harbingers of progressive atrophy in the earliest stages of AD. We now discuss these 
findings in greater depth, organised into sections pertaining to the type of risk factor. 
 
 
Familial AD 
In general, the prevailing evidence points to temporo-parietal atrophy in presymptomatic FAD 
mutation carriers, although non-significant and increased volumes have also been reported 
(Table 1). APP and PSEN1 mutation carriers (n = 13, age = 43) from four Swedish families 
showed reductions of cortical volumes in temporal and precuneus regions, even after correcting 
for gender and ApoE genotype (Thordardottir et al., 2015). These findings are congruent with an 
earlier longitudinal study of an aged-matched (n = 9, age = 44) sample of APP and PSEN1 
mutation carriers who expressed an accelerated course of thinning in similar regions such as the 
entorhinal cortex, parahippocampal gyrus, posterior cingulate cortex and the precuneus. In 
particular, cortical thinning in the posterior cingulate cortex and the precuneus were found 1.8 
and 4.1 years prior to diagnosis in mutation carriers (Knight et al., 2011). The effects of PSEN1 
mutations on early structural aberrations have been investigated in the Colombian Alzheimer‟s 
Prevention Initiative Registry, which includes more than 1500 living members from the largest 
known autosomal-dominant AD kindred, 30% of whom are carriers of the PSEN1 E280A 
mutation (Lopera et al., 1997). Carriers from this kindred have an estimated median age of 44 
years at onset of MCI and 49 years at onset of AD (Acosta-Baena et al., 2011). Echoing the 
aforementioned studies (Knight et al., 2011; Thordardottir et al., 2015), structural imaging 
analyses from this cohort have revealed an „AD signature‟ of cortical thinning in both mid-life 
(age = 38) (Quiroz et al., 2013), most prominently in parietal cortices and precuneus. In addition, 
Quiroz and colleagues reported that these cortical changes occurred 6 years before symptom 
onset and 11 years prior to AD diagnosis (Quiroz et al., 2013). Notably, the parietal predilection 
was similarly found in a Voxel Based Morphology (VBM) analysis of younger PSEN1 mutation 
carriers (n = 20; age = 22) (Reiman et al., 2012). 
 However, the literature on presymptoamatic FAD mutation carriers remains mixed with negative 
findings (Apostolova et al., 2011) as well as reports of cortical thickening in the precuneus and 
temporo-parietal cortices (Fortea et al., 2010). Interestingly, Fortea and colleagues showed that 
these regions exhibited an inverse pattern of cortical thinning in symptomatic carriers, possibly 
reflecting a compensatory process that could not be sustained as the disease progressed (Fortea et 
al., 2010). 
 
The cortical expressions of FAD mutations also appear to be complex in the youngest 
populations. Unlike the atrophic cortical profile expressed in older aged carriers (Quiroz et al., 
2013; Reiman et al., 2012),  children (9 – 7 years  old) with PSEN1 mutation carriers had larger 
grey matter volumes in temporo-parietal regions, particularly in the parahippocampal gyrus and 
temporal pole (Quiroz et al., 2015). Interestingly, an opposite effect of thinner entorhinal cortex 
was found in children and adolescent ApoE4 carriers (age = 18) (Shaw et al., 2007). Shaw and 
colleagues also reported a stepwise increase in cortical thickness in the entorhinal cortex: from 
the thinnest cortex in ApoE4 carriers, through an intermediate thickness in ApoE3 carriers, to the 
thickest cortex in carriers of the ApoE2 allele (Shaw et al., 2007). At an even younger age, 
ApoE4 infant carriers (6 – 22 months old) also showed a combination of greater volumes in 
frontal regions and decreased volumes in the precuneus, cingulate, and temporal regions (Dean et 
al., 2014). These studies suggest potentially differential effects of PSEN1 and ApoE4, which 
could in turn be modulated by age. Future studies are needed to clarify the role of PSEN1 and 
ApoE4 in neurodevelopmental processes and how alterations in these processes (i.e. synaptic 
pruning and cortical gyrification) may be relevant to the future development of AD. 
Apolipoprotein E4  
Imaging studies in preclinical AD have attempted to characterise ApoE4-related cortical changes 
in preclinical AD, although the literature is fragmented with highly discrepant findings (Table 2).  
Generalised volumetric loss and cortical thinning in ApoE4 carriers have been reported in 
several studies (Crivello et al., 2010; Fan et al., 2010; Hashimoto et al., 2009; Lemaître et al., 
2005), even in younger groups below 60 (Burggren et al., 2008; Wishart et al., 2006). More 
specifically, entorhinal thinning and medial temporal lobe volume loss have been observed in 
heterozygous ApoE4 carriers relative to non-carriers (Burggren et al., 2008; Fan et al., 2010; 
Wishart et al., 2006), and others have demonstrated congruent findings showing a steeper 
trajectory of age-related thinning of widespread cortical thinning in individuals with at least one 
ApoE4 allele (Espeseth et al., 2008).  
 
However, these findings are in contrast with studies reporting no structural difference in 
heterozygous ApoE4 carriers compared to non-carriers (Cherbuin et al., 2008; Crivello et al., 
2010; Heise et al., 2011; Lemaître et al., 2005) (Age range: 69 – 75). The disparity of findings 
has prompted debate about the existence of a gene-dose effect of ApoE4 on cortical atrophy, 
particularly in light of other studies demonstrating medial temporal lobe atrophy and accelerated 
cortical atrophy only in homozygous ApoE4 carriers of comparable age (Chen et al., 2007; 
Crivello et al., 2010; Lemaître et al., 2005) (Age range: 55 – 75). 
 
Family history 
Some studies have compared the presymptomatic imaging endophenotypes of maternal family 
history (FHm) against paternal family history (FHp) in AD (Berti et al., 2011; Honea et al., 2011, 
2010; Mosconi et al., 2014). Using VBM approaches, these studies have converged to reveal a 
more severe extent of cortical atrophy in FHm compared to controls and FHp (Berti et al., 2011; 
Honea et al., 2010). Conversely, no structural differences were found between FHp and controls 
(Berti et al., 2011), although Honea and colleagues (Honea et al., 2010) reported additional 
frontal lobe and precuneus atrophy in the FHp group compared to the controls. A subsequent 2-
year duration longitudinal VBM study showed progressive atrophy in the precuneus and 
parahippocampal cortex of FHm individuals compared to both FHp and controls (Honea et al., 
2011). Another VBM study identified a „parent-dose effect‟ where individuals (age = 56) with 
both FHm and FHp showed the most severe atrophy in the temporal cortex, while additional 
parietal atrophy was found in the FHm group compared to FHp (Mosconi et al., 2014). Overall, 
these observations of greater atrophy in individuals with FHm are in agreement with evidence 
that maternal transmission of AD is associated with more severe hypometabolism (Mosconi et 
al., 2009) and memory impairment (Debette et al., 2009). However, other VBM studies have not 
found a parent-of-origin effect on cortical atrophy in middle-aged groups (age range: 53 - 57) 
(Okonkwo et al., 2012; Ten Kate et al., 2016). For instance, both FHm and FHp groups showed 
precuneus atrophy compared to individuals without a family history (Ten Kate et al., 2016). 
 
Interactions between apolipoprotein E4 and family history 
The potential interactions between ApoE4 carriage and family history on structural morphology 
have also been a topic of investigation. In the Framingham Offspring study, a higher rate of 
global brain atrophy over 6 years was only found in ApoE4 carriers with a positive family 
history of AD (Debette et al., 2009). Through an exploratory VBM analysis that is unrestricted 
by an AD-ROI mask, another study found differential effects of ApoE4 and family history on 
regional atrophy in a relatively younger sample. ApoE4 carriage (age = 61) was associated with 
striatal atrophy whereas family history (age =57) was associated with atrophy in the precuneus 
(Ten Kate et al., 2016). Individuals characterised by an extreme phenotype of “double risk” (i.e. 
positive family history and ApoE4) also demonstrated bilateral insular atrophy compared. This 
finding is particularly noteworthy as that it has not been reported in the literature of preclinical 
dementia (Ten Kate et al., 2016)., even though it has been implicated in mild cognitive 
impairment with PD and AD (Mak et al., 2014b; Sluimer et al., 2009). 
 
TOMM40 gene 
Few studies have characterised the effect of TOMM40 poly-T length on cortical changes in 
cognitively healthy individuals (Johnson et al., 2011). In a search-restricted VBM study 
focussing on homozygotic ApoE3 middle-aged adults, a dose-dependent increase in the Very-
Long (VL) TOMM40 polymorphism was associated with atrophy in the precuneus and posterior 
cingulate (no VL alleles < Short/VL heterozygotes < VL/VL homozygotes) after adjusting for 
age and total intracranial volumes. It is worth mentioning that the precuneus and posterior 
cingulate cortex have repeatedly been implicated in this article as well as other studies in AD 
(i.e. hypometabolism, decreased white matter integrity and macroscopic atrophy). A network 
perspective (discussed in greater detail later) could offer some insights into the preferential 
vulnerability of these regions across the spectrum of dementia. The precuneus and posterior 
cingulate cortex are heavily involved in the default mode network. Interestingly, network 
analyses have consistently identified these regions as hubs with dense anatomical connections 
occupying a central position in the topology of brain networks (van den Heuvel and Sporns, 
2013). However, a centrality confers a high biological cost (i.e. increased metabolic demands) 
and renders these regions susceptible to disease-related processes (Crossley et al., 2014). At 
present, further studies, are warranted to investigate the link between TOMM40 variations and 
imaging changes at the cross- and longitudinal levels. 
 
Brain-derived neurotrophic factor gene 
Considering its critical role in neuroplasticity underlying learning and memory in the 
hippocampus, the brain-derived neurotrophic factor (BDNF) gene represents another potential 
risk factor for AD, although its influence on brain morphology is relatively understudied in the 
context of preclinical AD. A single nucleotide polymorphism in the BDNF gene produces a 
valine to methionine (Val66Met) amino acid substitution that affects intracellular packaging and 
activity-dependent secretion of the BDNF, in turn affecting human memory function (Chen, 
2004; Egan et al., 2003) and hippocampal morphology (Bueller et al., 2006). In a retrospective 
longitudinal study over 3 years, Hashimoto and colleagues were the first to report a significant 
effect of the Val66MET polymorphism in preclinical AD, showing accelerated atrophy in the 
precuneus and cingulate regions in MET-BDNF carriers compared to VAL-BDNF carriers 
(Hashimoto et al., 2009). 
  
6. SUBCORTICAL ATROPHY 
Hippocampus 
Hippocampal volumetry is one of the most validated, accessible and widely used biomarkers in 
AD. The hippocampus is an early preferential target of neurofibrillary tangles (Braak and Braak, 
1991), and is markedly atrophied at the time of AD diagnosis, with a meta-analysis reporting 
approximately 25% smaller volumes compared to age-matched controls (Shi et al., 2009).  
 Similarly, the neuroimaging literature suggests a predilection of hippocampal atrophy in 
presymptomatic individuals, although evidence regarding the effects of ApoE4 remains 
inconclusive. Cross-sectionally, studies have reported significant hippocampal atrophy in ApoE4 
carriers (den Heijer et al., 2002; Honea et al., 2009; Lemaître et al., 2005; Lind et al., 2006; 
Tohgi et al., 1997), as well as younger FAD mutation carriers (age range:  21-45) (Bateman et 
al., 2012; Fleisher et al., 2015; Ridha et al., 2006). However, there are just as many notable 
exceptions of negative findings in cross-sectional comparisons (Apostolova et al., 2011; 
Cherbuin et al., 2008; Gold et al., 2010; Lupton et al., 2016; Lyall et al., 2013; Protas et al., 
2013). Indeed, one of the primary limitations of cross-sectional designs concerns the inter-
individual variability of brain structures within a study sample. Longitudinal imaging studies 
wherein the same individuals are tracked over time may be more sensitive to subtle atrophy, 
particularly during the preclinical phase of AD. Lending support to this notion is the 
homogeneity of findings across longitudinal studies. For instance, increased rates of 
hippocampal atrophy were found in ApoE4 carriers (Cohen et al., 2001; Moffat et al., 2000) and 
individuals with family history (Okonkwo et al., 2012) over time, despite showing relative 
preservation at baseline. In addition to the independent effect of family history on hippocampal 
volumes, there is also increasing evidence that family history can interact with ApoE4. In the 
longitudinal study from the Wisconsin Registry for Alzheimer‟s Prevention (WRAP), Okonkwo 
and colleagues demonstrated that the effect of family history on hippocampal atrophy was more 
pronounced in non-carriers of ApoE4 (Okonkwo et al., 2012). These findings are consistent with 
other longitudinal studies of homozygous ApoE4 carriers (Crivello et al., 2010), younger FAD 
genetic mutation carriers (age < 60) (Fox et al., 1996; Ridha et al., 2006; Schott et al., 2003).  
 Fewer studies have addressed the effect of ApoE4 on the hippocampus in healthy younger adults 
(age < 30). The small but growing literature has yielded equivocal findings, where both atrophy 
(Alexopoulos et al., 2011; O‟Dwyer et al., 2012) and preservation (Khan et al., 2014; Mondadori 
et al., 2007; Richter-Schmidinger et al., 2011) have been reported. In a large cohort of more than 
1400 adolescents (age = 14), Khan and colleagues did not demonstrate any hippocampal volume 
(automatically segmented and normalised for ICV) differences between ApoE4 carriers and non-
carriers (Khan et al., 2014). This is consistent with other studies of similarly aged samples (Heise 
et al., 2011; Mondadori et al., 2007; Richter-Schmidinger et al., 2011). Intriguingly, Mondadori 
and colleagues have also reported an association of ApoE4 with better episodic memory 
compared to ApoE2 and ApoE3 in a sample of 340 young adults (age = 22) (Mondadori et al., 
2007). Considered in tandem with previous evidence where ApoE4 has been associated with 
higher IQ scores in younger adults (Yu et al., 2000) and enhancement of hippocampal long-term 
potentiation (Kitamura et al., 2004), it could be hypothesised that ApoE4 mediates 
neurodevelopmental resilience (Oría et al., 2005) (Brazil study) and enhanced intellectual 
function in children and young adults. It is thus possible that, through an interaction with age, the 
effect of ApoE4 transitions from a quiescent or even neuroprotective role from childhood to 
young adulthood before exerting a deleterious effect on cognition (Lothian Birth Cohort 1921) 
(Schiepers et al., 2012) and brain morphology in later life. Key to our ability to understand this 
would be studies that can provide regular follow up of participants from before, during and after 
this transition point. 
 
Amygdala and striatal structures 
Several post-mortem studies have also reported AD neuropathology in the amygdala (Arriagada 
et al., 1992; Tsuchiya and Kosaka, 1990), although its vulnerability in preclinical AD remains to 
be established. Amygdala atrophy has been reported in presymptomatic ApoE4 carriers (den 
Heijer et al., 2002; Honea et al., 2009) with potential dose-dependent effects of ApoE4 (den 
Heijer et al., 2002). However, negative findings have been reported from other studies 
employing manual tracing (Cherbuin et al., 2008) and automated segmentation approaches 
(Lupton et al., 2016). 
 
Other subcortical regions including the thalamus, caudate and putamen have been implicated in 
presymptomatic FAD mutation carriers (Cash et al., 2013; Lee et al., 2012; Ryan et al., 2013). 
These findings run counter to a previous study in which presymptomatic FAD mutation carriers 
expressed an unexpected larger caudate whereas symptomatic carriers demonstrated an expected 
caudate atrophy relative to controls (Fortea et al., 2010). Given that the carriers were on average 
9.9 years from expected age at onset, Fortea and colleagues interpreted their findings to reflect a 
possible reactive neuronal hypertrophy and/or neuroinflammation early in the presymptomatic 
stage that could explain the initial increase in the volume of these structures, which then undergo 
progressive atrophy as the disease progresses. Consistent with their interpretations, we have 
recently shown that proinflammatory processes could be observed up to 10 years before 
diagnosis (Ritchie et al., 2016). Thus, these findings argue that structural imaging findings of 
presymptomatic familial AD should be interpreted in light of the temporal proximity to expected 
age of symptom onset. 
  
7. MICROSTRUCTURAL CHANGES IN PRECLINICAL DEMENTIA 
Over the last decade, there has been exponential progress in the development and application of 
diffusion tensor imaging (DTI) (Le Bihan, 2006) to study both grey and white matter brain 
structure during neurodevelopment and neurodegeneration. The breakdown of microstructural 
barriers (i.e. myelin) that normally constrain the Brownian motion of water molecules results in a 
quantifiable difference in the diffusion of water along white matter tracts that could be indexed 
by various DTI metrics. Fractional anisotropy (FA) reflects the directional constraint (tendency 
for water diffusion to occur in a single direction) of the water diffusion along axons, and lower 
FA is commonly interpreted as disrupted microstructural integrity. Mean diffusivity (MD) is a 
measure of the average rate of diffusion in all directions and generally increases with axonal 
degeneration and demyelination. Such DTI changes are not visible on conventional structural 
MRI sequences, and previous evidence suggests that they could precede grey matter atrophy 
(Kantarci et al., 2005) and the appearance of amyloid and tau pathology (Desai et al., 2009).  
 
DTI has been increasingly applied to investigate early microstructural deficits in FAD genetic 
mutation carriers (Li et al., 2015; Ringman et al., 2007; Ryan et al., 2013; Sánchez-Valle et al., 
2016), cognitively normal ApoE4 carriers (Adluru et al., 2014; Bendlin et al., 2010; Heise et al., 
2011; Honea et al., 2009; Kim et al., 2015; Lyall et al., 2014; Nierenberg et al., 2005; Persson et 
al., 2006; Ryan et al., 2011; Smith et al., 2010), and individuals with family history of AD 
(Hawkins et al., 2015; Kim et al., 2015; Smith et al., 2010). 
 
Familial AD  
Global FA was reduced in preclinical FAD mutation carriers (age = 35), and this effect was most 
pronounced in the fornix and white matter tracts of the orbitofrontal region during the 
presymptomatic stage (Ringman et al., 2007). Li and colleagues reported that, in the absence of 
grey matter atrophy, presymptomatic FAD mutation carriers (age = 43) expressed higher MD but 
not FA in the longitudinal fasciculus and cingulum (Li et al., 2015). In contrast, other studies 
have not found significant changes in DTI metrics in similarly aged presymptomatic FAD 
mutation carriers (Parra et al., 2015; Sánchez-Valle et al., 2016), although significant FA 
decrease and MD increase were found in the corona radiata and corpus callosum in the 
symptomatic group (Sánchez-Valle et al., 2016). Interestingly, one study reported that 
presymptomatic carriers (age = 38) showed significantly decreased MD in the right hippocampus 
and the cingulum, as well as increased FA in the bilateral thalamus and left caudate (Ryan et al., 
2013). The authors speculated that these seemingly paradoxical findings could reflect earlier 
axonal insults in the pathway towards subsequent neurodegeneration, such as initial microglial 
activation/accumulation and swelling of neurones and glial, which could, in turn, lead to a 
greater restriction on the Brownian motion of water molecules. 
 
Apolipoprotein E4 and family history  
Healthy individuals with ApoE4 are characterised by less white matter volume (Ready et al., 
2011) (age = 53) and a higher rate of myelin breakdown in an older sample (Bartzokis et al., 
2006) (age = 66). Furthermore, ApoE4 carriers have also showed decreased FA in widespread 
white matter tracts associated with temporal lobe structures, including the cingulum (Smith et al., 
2010) (age = 58), corpus callosum, and longitudinal fasciculus (Heise et al., 2011; Lyall et al., 
2014). In addition, the microstructural integrity of the medial temporal lobe could be highly 
susceptible to the earliest pathology in preclinical AD. Other studies have found convergent 
ApoE4-related FA decreases in parahippocampal gyrus white matter (Honea et al., 2009; 
Nierenberg et al., 2005) and left hippocampus (Persson et al., 2006) in older cognitively normal 
individuals (age > 60). Considering the accumulating evidence of medial temporal lobe atrophy 
in presymptomatic ApoE4 carriers as described earlier (Section 4), it could be a case where white 
matter integrity is compromised through Wallerian degeneration. However, this argument is 
increasingly challenged by other multi-modal (DTI and T1) studies showing that presymptomatic 
individuals had decreased microstructural integrity of widespread regions – including the medial 
temporal fibre tracts – without total grey matter or hippocampal atrophy (Gold et al., 2010; Heise 
et al., 2011). Thus, further longitudinal studies are needed to elucidate the temporal sequence of 
microstructural and grey matter changes. 
 
Other studies have investigated the relative contributions of parental family history and ApoE4 
carriage to microstructural changes in presymptomatic individuals (Adluru et al., 2014; Bendlin 
et al., 2010; Gold et al., 2010) (age = 60). Individuals possessing both positive family history and 
ApoE4 showed the lowest FA in characteristic AD regions, such as the corpus callosum, 
cingulum, and medial temporal grey and white matter connections (Bendlin et al., 2010; Gold et 
al., 2010). However, these findings are also in contrast to another study, which did not show any 
ApoE4-related white matter changes, although individuals with a positive family history showed 
an unexpected FA increase in the corpus callosum and the superior longitudinal fasciculus 
(Adluru et al., 2014). In order to move beyond speculative interpretations of such DTI changes, 
the field needs more concerted attempts to validate FA or MD changes with histological data. In 
parallel, more longitudinal studies are needed to characterise the course of microstructural brain 
changes that occur at presymptomatic disease stage, and to investigate their associations with 
cognitive decline over time. 
 8. THE PRECLINICAL CONNECTOME 
Graph theoretical approach in brain networks 
While the studies reviewed in this paper have identified characteristic patterns of atrophy and 
microstructural deficits in the preclinical stages of AD, questions about their macro-level impact 
on the brain organisational properties remain unresolved. Increasing attention on these questions 
has coincided with the ascendancy of connectomics – an attempt to map the multitude of 
neuronal connections in the brain – and graph theory as a joint-approach to quantify the large-
scale topological properties of the brain networks in neurodegenerative diseases (Alexander-
Bloch et al., 2013; Bullmore and Sporns, 2009). The field of connectomics also represents a 
paradigm shift away from the conventional segregated region-based approach towards an 
integrative perspective that considers the topological organization of the entire human cortex. 
Network-based analyses may be sensitive to aberrations not evident in brain structure because 
they take into account multivariate interactions and co-dependencies between brain regions as 
well as the integration of each region in the overall network architecture.  
 
Construction and statistical comparisons of structural networks 
The structural network could be derived from the structural covariance approach (i.e. inter-
regional correlations of cortical thickness) at the group level (Alexander-Bloch et al., 2013; 
Bernhardt et al., 2011; Mak et al., 2016) as well as similarity-based grey matter networks in 
individual subjects (Tijms et al., 2012). In addition, white matter tracts constituting the 
macroscale connectome can be constructed using diffusion tractography pipelines (Hagmann et 
al., 2008). Subsequently, network properties such as path length and clustering are quantified 
from these networks using graph theoretical concepts and subsequently normalised against 
benchmark (i.e. random) networks. Statistical comparisons are highly dependent on the nature of 
the networks. For instance, metrics from single-subject DTI and GM networks are typically 
compared using independent Student T-tests or ANOVA to correct for covariates (Tijms et al., 
2013a), while comparisons of group-level cortical thickness connectomes would necessitate non-
parametric permutation testing or bootstrapping simulations across network densities (5 – 40%)  
(Bernhardt et al., 2011; Mak et al., 2016). 
 
Summary of connectomic changes in mild cognitive impairment and Alzheimer’s disease 
A consistent finding across the literature indicates the brain networks are organised with an 
efficient „small-world' topology, reflecting an optimal balance of (a) short characteristic path 
length (CPL), facilitating efficient integration of information from multiple brain regions using a 
relatively short distance; and (b) high clustering coefficient (CC), resulting in dense inter-
connections between adjacent brain regions (Rubinov and Sporns, 2010). Recent studies have 
characterised the structural brain networks in AD and MCI (see (Tijms et al., 2013b) for  a 
review), and while there is a general agreement that AD and MCI are associated with changes in 
network properties, there is a worrying lack of consensus about the directionality and 
interpretation of these changes. For instance, AD has been characterised with a pairing of 
increased CPL and CC compared to controls (Lo et al., 2010). This increased CPL might reflect 
an abnormal loss of circuit „short-cuts‟, resulting in increased local segregation of information 
transfer at the expense of global integration. In contrast, others have reported decrease clustering 
in AD (Tijms et al., 2013a). With regards to the potential utility of graph theory as a biomarker 
for subsequent disease progression, the Randić index – the degree to which highly connected 
nodes are also connected to other highly connected nodes (i.e. a rich club) – obtained at baseline 
could distinguish MCI subjects who remained stable over 3 years from those who converted to 
AD (Phillips et al., 2015). 
 
Topology of brain networks in preclinical AD 
We have identified only two previous studies investigating the macroscale impact of focal brain 
changes in preclinical AD  (age range: 61 - 67). Using DTI tractography, Brown and colleagues 
(Brown et al., 2011) reported that cognitively normal ApoE4 carriers showed a significant 
decrease of small-worldness with age that was largely driven by the loss of local clustering. 
Interestingly, key brain regions in the default mode network also showed less interconnectivity 
(Brown et al., 2011). Chen and colleagues (Chen et al., 2015) reported a modulating effect of the 
rs405509 genotype – a newly recognised AD-related polymorphism located in the ApoE 
promoter region (Lambert et al., 2002) – on structural covariance networks in cognitively normal 
elderly subjects. Only the non-risk group (rs405509 G-allele carriers) expressed cortical 
thickness covariance between the left parahippocampal gyrus and left medial cortex. At present, 
the biological mechanisms that subserve structural covariance remains a contentious topic, 
although inter-regional correlations of cortical thickness have been found to partly overlap with 
underlying white matter connections (Gong et al., 2012). Future studies could use diffusion 
tractography to assess the microstructural integrity of the white matter tracts in question. 
 
9. PRECLINICAL DEMENTIA AND NORMAL AGEING 
It is now well established that the normal process of ageing is intrinsically related to progressive 
impairment of neural mechanisms and neurotransmitters (Mora et al., 2007), changes in 
cognition and behaviour, as well as morphological changes over time  (Fjell et al., 2009). Unlike 
the stereotypical localisations of temporo-parietal susceptibility in preclinical dementia, brain 
changes associated with normal aging appear to follow a non-linear trend (Ziegler et al., 2012) 
with strong effects in frontal cortices (Fjell et al., 2009). However, previous studies have also 
demonstrated thinning in regions that are known to be vulnerable to AD, such as age-related 
acceleration of entorhinal thinning (Fjell et al., 2014). In summary, the literature suggests that 
brain changes in preclinical dementia are superimposed on normal ageing, albeit with greater 
magnitude conferred by pathological amyloid and/or tau. Thus, the co-localisations of atrophy in 
normal and preclinical dementia underscore the importance to adjust for age as a covariate in all 
imaging comparisons. 
 
10. FUTURE DIRECTIONS 
Need for more longitudinal studies 
Most of the studies investigating the effects of AD risk factors on brain structure often employed 
a cross-sectional design in which brain structure was compared between carriers and non-
carriers. While convenient, this design precludes the evaluation of the effects of AD risk factors 
on intra-individual progression of atrophy. Longitudinal studies including serial scans provide an 
assessment of individual trajectories of brain changes and give insight into the variability of 
brain changes between different persons. Future prospective studies over longer time periods are 
required to determine the predictive utility of various biomarkers for transitioning to AD and 
elucidate within-individual trajectories of the biomarkers. It is encouraging that multiple 
longitudinal preclinical cohorts are pursuing these endeavours. Notably, the WRAP project 
presently has 7 – 10 years worth of multimodal imaging data in a late middle-age cohort. The 
PREVENT study (Ritchie et al., 2013), which is an on-going study from our group, is also 
collecting large amounts of imaging data (including MRI, DTI, MRS and fMRI) from people 
aged 40 to 59 at baseline, as well as detailed neuropsychological assessment using the 
COGNITIO test battery (Ritchie et al., 2014) designed for pre-clinical cognitive assessment as 
well as genetic analyses. In the context of autosomal dominant AD and individuals in the earliest 
stages of the disease, ongoing longitudinal analyses of imaging data from the Dominantly 
Inherited Alzheimer Network (DIAN) (Cash et al., 2013), the Alzheimer‟s Prevention Initiative‟s 
Columbia Registry (Lopera et al., 2013) and others (Yau et al., 2015) will clarify not only the 
spatial extent but the trajectory of preclinical brain changes with respect to estimated age of 
onset AD. These collective efforts will also facilitate important studies to investigate the 
generalisability of imaging findings in FAD to sporadic AD. 
 
Investigating hippocampal subfields 
The hippocampus is one of the most heavily implicated regions in this review, suggesting 
preferential predilection even at the earliest stages of AD. However, the influence of certain risk 
factors, such as ApoE4, on hippocampal volumetry remains highly controversial with 
inconclusive findings. Apart from some of the common culprits such as sample heterogeneity 
and adjusted covariates, these divergent findings could also be attributed to non-uniform effects 
of the E4 allele across the histologically and functionally distinct subfields of the hippocampus. 
Consequently, treating the hippocampus as a unitary structure would have obscured these subtle 
changes. Local analyses of the hippocampus are increasingly recognised as a viable method to 
characterise the involvement of cytoarchitectonic regions in the pathology of neurodegenerative 
diseases (de Flores et al., 2015; Mak et al., 2015b). Based on a probabilistic Bayesian approach, 
automated techniques for the segmentation of hippocampal subfields based on ex vivo training 
data have been improved and are publicly available (Iglesias et al., 2015) for the analyses of 
large datasets. We envisage that this will become a promising research area that is capable of 
detangling the differential effects of preclinical AD risk factors on specific sub-regions. 
 
Multi-modal imaging 
More studies are needed to investigate the potential influence of amyloid burden (PET imaging 
and CSF amyloid levels) in the context of the structural brain changes reviewed in this paper. 
Characteristic AD patterns of cortical thinning in temporal regions have been reported in 
cognitively normal AB+ individuals (Dickerson et al., 2009). Longitudinal studies have found 
that cognitively normal individuals with high amyloid deposition showed accelerated cortical 
atrophy in other susceptible regions of the brain, including the precuneus, medial temporal lobe, 
and other temporo-occipital cortices (Chetelat et al., 2012; Ewers et al., 2012). Several studies 
have also considered the interaction of amyloid with tau in cortical changes, with two 
longitudinal studies indicating that amyloid-associated thinning in the entorhinal cortex occurred 
only in the presence of elevated CSF phospho-tau (Desikan et al., 2013, 2011).  For a thorough 
review of amyloid imaging in cognitively normal individuals within at-risk populations, the 
reader is referred to Chételat et al (Chetelat et al., 2013). Beyond this, a combination of in vivo 
multi-modal biomarkers is also expected to provide additive information to quantify AD 
pathology in the preclinical phase. This approach is advocated based on an updated proposal of 
the pathophysiological trajectory in AD (Jack et al., 2013). For instance, a plateauing effect has 
been demonstrated in amyloid deposition during the later stages of AD. In contrast, 
neurodegeneration and tau pathology appear to worsen in close synchrony with cognitive decline 
(Jack et al., 2013). As a corollary, it follows that combining amyloid pathology and structural 
imaging may allow a finer characterization of preclinical staging (Jack et al., 2016; Sperling et 
al., 2011).  In addition, the recent advent of in vivo tau imaging represents an exciting frontier to 
establish the relation of tau accumulation to downstream atrophy and perform. Ideally, these 
models would also eventually include relevant comorbid pathological events such as 
cerebrovascular changes and inflammation. 
 
11. CONCLUSION 
The use of structural neuroimaging techniques to study presymptomatic individuals offers a 
valuable time window to identify cerebral abnormalities of AD during the preclinical phase of 
the disease, with changes predating the onset of symptoms as early as up to a decade. Ultimately, 
clinical trials of interventions aimed at preclinical AD will likely hinge on two parallel 
endeavours: (a) fuller understanding of the complex effects of classical risk factors on both 
clinical and imaging characteristic in preclinical AD (i.e. is there a non-linear effect of ApoE4 
and FAD mutations through ageing); and (b) identification of reliable and sensitive outcome 
measures (or combinations of outcome measures) that are capable of tracking disease 
progression in the absence of cognitive impairment at an individual level.  
 
In the context of structural markers, this review has provided a comprehensive summary of 
preclinical structural disruptions occurring across different scales, from microstructural deficits 
in white matter tracts, volumetric loss in subcortical structures and cortical thinning, to network 
effects in the connectome. Overall, the literature reveals a preferential vulnerability of highly 
select brain regions that overlap with structures that are noted to be affected in prodromal AD 
and sporadic AD itself. They include the medial temporal lobe and its connected white matter 
tracts, temporo-parietal cortices, hippocampus, precuneus, as well as the cingulum bundle and 
the corpus callosum.  
 
Yet, the literature of structural changes in relation to risk factors was highly fragmented – 
particularly in ApoE4 carriers – with many discrepant findings of structural preservation and 
even hypertrophy in a small number of studies. Two caveats should be considered during the 
interpretation and comparison of imaging findings in preclinical AD. Firstly, AD has a 
multifaceted aetiology that is set against a convoluted polygenic background. Secondly, genetic 
risk factors such as ApoE4 could exert deleterious effects via multiple mechanisms with 
potentially differential effects across different stages of the lifespan (Liu et al., 2013). Therefore, 
the heterogeneous findings could be attributed to a range of factors: (a) single-modality imaging 
studies being unable to accurately characterise the full spectrum of ApoE4 effects; (b) variability 
in the demographics, both within and across studies, (c) variable length of time prior to onset of 
symptoms and (d) methodological differences in acquisition parameters, quantification methods 
(e.g. cortical thickness, voxel-based morphometry, region-of-interest approaches). Finally, there 
are also suggestions from the literature that ApoE4 and family history could interact to affect 
both grey and white matter, even at the asymptomatic stages. 
 
We conclude that while structural imaging measurement is promising, more research and 
validation studies are needed before neuroimaging research can inform decisions regarding the 
adoption of structural measures in future treatment and prevention trials. In particular, there 
needs to be an incorporation of age or distance from dementia diagnosis as an interactive term in 
any modelling work which would benefit in particular from frequent longitudinal follow up. 
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Table 1.  Asymptomatic changes in FAD mutation carriers 
 
 
Study 
 
Definition 
of 
preclinical 
dementia  
 
 
Imaging 
modality 
and 
acquisitio
n 
 
Design and 
analyses  
 
Sample 
(Mean age ± SD)  
 
Main findings  
Cash et al. 
(2013)  
 
* DIAN 
 
FAD 
mutation 
carriers: 
Mostly 
PSEN1 
  
3T  
T1 MRI 
Cross-
sectional: 
VBM in 
SPM8 
GM  
WM 
Non-carriers: n = 73 
(40.6 ± 8.9) 
Presymptomatic 
carriers:  
n = 69 (34.1 ± 8.9) 
NS, trend for 
decreased 
thalamus GM 
for carriers 
closer to EYO 
 
Bateman et al. 
(2012) 
* DIAN 
FAD 
mutation 
carriers: 
PSEN1 and 
APP 
3T 
T1 MRI 
Cross-sectional: 
Hippocampus 
from Freesurfer 
Non-carriers: n = 40 
(39.5 ± 8.9) 
Mixed Carriers: n = 88 
(39.1 ± 10.3) 
Hippocampal 
atrophy 
Fleisher et 
al. (2015) 
 
* API 
Columbian 
kindred 
FAD 
mutation: 
PSEN1 
1.5T 
MRI 
Cross-
sectional: 
Hippocampus 
from 
Freesurfer 
Non-carriers: n = 22  
(33 ± 9)  
Carriers:  
n  = 20 (32 ± 9)  
  
Hippocampal 
atrophy 
Quiroz et al. 
(2013) 
 
* API 
Columbian 
kindred 
FAD 
mutation: 
PSEN1  
1.5T  
T1 MRI  
Cross-
sectional:  
CTh thickness 
in 
AD-signature 
ROIs from 
Freesurfer 
Non-carriers: n = 22  
(39.5 ± 6.2) 
Carriers: n = 18 
(38.2 ± 4.5)  
Thinner cortex 
in AD-
signature ROI 
 
Quiroz et al. 
(2015) 
 
* API 
Columbian 
kindred 
FAD 
mutation: 
PSEN1 
1.5T  
T1 MRI  
Cross-
sectional:  
VBM  
Non-carriers: n = 19  
(13 ± 3)  
Carriers: n = 18  
(13 ± 2)  
Increased GM 
volume in 
temporal 
regions  
Reiman et 
al. (2012) 
 
* API 
Columbian 
kindred 
PSEN1  
 
1.5T  
T1 MRI  
Cross-
sectional:  
Restricted 
VBM based 
on findings in 
AD 
 
Non carriers: n = 24 
(22 ± 2)  
Carriers: n = 20  
(22 ± 3) 
 
Reduced GM 
volume in 
parietal 
regions 
Parra et al. PSEN1 1.5T Cross- Non carriers: n = 21  NS 
(2015) 
 
* API 
Columbian 
kindred 
DTI sectional: 
FA and MD 
from FSL; 
ROI  
 
 
(39.3 ± 83) 
Carriers: n = 18  
(35.1 ± 5.5) 
 
 
 
Notes: This abbreviated table contains highlighted studies in FAD that have more than 15 
subjects per group, and extra attention was afforded to longitudinal studies. Abbreviations: NS = 
No significant findings; APP = Amyloid precursor protein; PSEN1 = Presenilin 1; EYO = 
Estimated Year to Onset; ApoE4 = Apolipoprotein E4; DIAN = Dominantly Inherited Alzheimer 
Network; WRAP = Wisconsin Registry for Alzheimer Prevention; FH = family history; FA = 
Fractional anisotropy, MD = Mean diffusivity, ROI = Regions of Interest; CTh = Cortical 
thickness, GM = Grey matter; WM = White matter; AAL = Automated Anatomical Labeling, 
VBM = Voxel based morphometry, SPM = Statistical Parametric Mapping. 
 
 
 
  
TABLE 2.  Asymptomatic changes related to ApoE4 carriage and family history 
 
 
Study 
 
Definition of 
preclinical 
dementia  
 
 
Imaging 
modality 
and 
acquisition 
 
Design and 
analyses  
 
Sample 
(Mean age ± 
SD)  
 
Main findings  
Dean et al. 
(2014) 
 
 
ApoE4 3T  
T1 and T2  
Cross-sectional: 
VBM in SPM 
MWF 
 
Carriers: n = 
60 
(391 ± 196) 
days 
Non-carriers: 
n = 102 
(366 ± 181) 
days 
 
 
Widespread 
reductions in 
MWF and GM. 
 
Greater MWF 
and GM volume 
in frontal 
regions. 
Espeseth et 
al. (2008) 
ApoE4 1.5T  
T1  
Cross-sectional: 
CTh from 
Freesurfer 
Carriers n = 
37  
(63.9 ± 7.9) 
Non-carriers: 
n = 59  
(64.9 ± 7.7) 
Cortical 
thickening in 
frontal and 
temporal regions. 
 
Steeper age-
related cortical 
thinning. 
Khan et al. 
(2014) 
 
* European 
IMAGEN 
project 
 
ApoE4 3T  
T1 MRI 
Cross-sectional: 
Hippocampus 
from Freesurfer 
Carriers: n = 
343 
(14.44 ± 
0.40) 
ApoE4-: n = 
1069  
(14.45 ± 
0.41) 
NS 
Lind et at. 
(2006) 
ApoE4  1.5T  
T1 MRI 
Cross-sectional: 
Hippocampus 
from manual 
tracing  
Carriers n = 
30  
(65.3 ± 7.9) 
Carriers: n = 
30  
(66.6 ± 8.3) 
Right 
hippocampal 
atrophy 
 
Lupton et al. 
(2016) 
 
* Multi-
cohort 
project 
ApoE4 
 
Field 
strength 
not 
reported 
MRI 
Cross-sectional: 
Hippocampus  
and amygdala 
from Freesurfer 
and FSL 
Healthy 
young: n = 
467 
(22.9 ± 3.3) 
Healthy 
older: n = 746  
No association of 
ApoE4 with 
hippocampal and 
amygdala 
volumes in 
healthy adults. 
(75.3 ± 5.9) 
Lyall et al. 
(2013) 
 
* Lothian 
Birth Cohort 
1936 
 
ApoE4 
TOMM40 
1.5T 
T1 MRI 
Cross-sectional: 
Hippocampus 
from FSL 
Total n = 655 
(72.7 ± 0.7)  
Subgroups 
based on 
ApoE4 and 
TOMM40 
NS 
Protas et al. 
(2013) 
ApoE4 MRI Cross-sectional: 
Hippocampus 
from a semi-
automated 
technique  
Homozygotic 
carriers: n = 
31 
(55.5 ± 5.1) 
Heterozygotic 
carriers: n = 
42 
(55.9 ± 4.0) 
Non-carriers: 
n = 76 
(56.5 ± 4.7) 
NS 
Richter-
Schmidinger 
et al. (2011) 
ApoE4 
BDNF-
Met66 
1.5T 
T1 MRI 
Cross-sectional: 
Hippocampus 
from manual 
tracing 
Non-carriers: 
n  = 117  
(24.6 ± 3.1) 
Carriers n  = 
18  
(24.1 ± 3.8) 
 
BDNF 
Met66-: n = 
84 
(24.9 ± 3.6) 
BDNF 
Met66+: n = 
51 
(23.9 ± 2.3) 
NS 
 
Ten Kate et 
al. (2016) 
 
* Gipuzkoa 
Alzheimer 
Project 
ApoE4 and 
FH  
3T 
T1 MRI 
Cross-sectional: 
VBM in SPM  
 
FH-ApoE4-: 
n = 55  
(58.4 ± 7.0) 
FH-ApoE4+:  
n = 12 
(61.1 ± 9.9) 
FH+ApoE4-: 
n = 166  
(56.5 ± 6.6) 
FH+ApoE4+: 
n = 62  
(54.9 ± 6.0) 
Relative to 
controls, ApoE4 
carriers showed 
reduce striatal 
volumes while 
FH+ had right 
precuneus 
atrophy. 
 
Similar atrophy 
patterns in 
maternal and 
paternal FH. 
 
Cherbuin et 
al. (2008) 
ApoE4  1.5T  
T1 MRI  
  
Cross-sectional: 
VBM,  
Hippocampus 
and amygdala 
from manual 
tracing 
Carriers: n = 
89  
(62.4 ± 1.5) 
Non-carriers: 
n = 242  
(62.7 ± 1.4) 
NS 
Crivello et 
al. (2010) 
ApoE4 1.5T 
T1 MRI 
Longitudinal: 
Hippocampus  
from AAL 
ApoE4+/+: n 
= 14  
(71.0 ± 2.3) 
ApoE4+/-: n 
= 239 
(72.0 ± 3.9) 
ApoE4-/-: n = 
933 
(72.4 ± 4.0)  
Higher rate of 
hippocampal 
atrophy in 
ApoE4 
homozygotes 
relative to 
heterozygotes 
and non-carriers. 
den Heijer 
et al. (2002) 
ApoE4 1.5T  
T1 MRI  
Cross-sectional: 
Hippocampus 
and amygdala 
from manual 
tracing, global 
brain atrophy 
from visual 
rating 
ApoE2: n = 
120  
(72 ± 7) 
ApoE3/E3: n 
= 568  
(73 ± 7)  
ApoE4: n = 
261  
(71 ± 7) 
ApoE4 carriers 
showed more 
hippocampal and 
amygdala 
atrophy 
compared to 
ApoE3 carriers. 
 
No difference in 
whole brain 
measurements. 
Honea et al. 
(2011)  
 
 
*KU Brain 
Aging 
project 
 
 
ApoE4 and 
FH 
 
3T  
T1 MRI 
Longitudinal: 
Whole brain 
atrophy rate 
VBM 
 
FH maternal: 
n  = 11  
(69 ± 6) 
FH paternal: 
n = 10  
(75 ± 8)  
FH-: n = 23  
(74 ± 7) 
Combined FH+ 
showed increased 
whole brain 
atrophy 
compared to FH-. 
 
Only FHm 
showed 
longitudinal 
brain atrophy in 
precuneus and 
hippocampal 
regions 
compared to FH- 
and FHp. 
 
ApoE4 carriers 
showed more 
frontal atrophy 
compared to non-
carriers. 
Okonkwo et 
al. (2012) 
 
* WRAP 
ApoE4 and 
FH 
3T  
T1 MRI 
Longitudinal: 
VBM restricted 
to search 
volume 
encompassing 
AD regions 
 
 
 
FH+ApoE4-: 
n = 27  
(52.78 ± 
6.77)  
FH+ApoE4+: 
n = 33 (53.91 
± 5.83) 
FH-ApoE4-: 
n = 40  
(55.48 ± 
5.99) 
FH-ApoE4+: 
n = 8  
(48.13 ± 
5.94) 
Those with FH 
and ApoE4 
showed 
significant 
atrophy in 
posterior 
hippocampus. 
 
No effects of FH 
or ApoE4 on GM 
volumes at 
baseline. 
Shaw et al. 
(2007) 
 
 
ApoE4 1.5T 
T1 MRI  
Longitudinal: 
CTh from 
manual tracing 
of ROI 
ApoE4+: n = 
65  
(18.0 ± 2.3) 
ApoE2: n = 
29 
(18.9 ± 1.3) 
ApoE3: n = 
145 
(16.0 ± 4.0) 
Reduced 
entorhinal 
thickness in 
ApoE4 carriers. 
 
No evidence of 
accelerated 
cortical thinning 
in ApoE4 
carriers. 
Debette et 
al. (2009) 
 
* 
Framingham 
Offspring 
Study 
ApoE4 and 
FH 
1/1.5T  
T2 MRI 
Longitudinal: 
Global brain 
volume 
Hippocampus 
from manual 
tracing  
FH: n = 285  
(62.7 ± 8.4) 
FH-: n = 432  
(57.0 ± 7.6) 
 
Only individuals 
with FH and 
ApoE4 showed 
higher rate of 
global brain 
atrophy. 
Adluru et al. 
(2014)  
 
* WRAP 
ApoE4 and 
FH 
3T  
DTI  
Cross-sectional: 
AD ROIs 
Total n = 358  
FH+: (60.29 
± 6.89) 
FH-: (62.96 ± 
5.84) 
ApoE4+:  
(60.12 ± 
6.81) 
ApoE4-:  
(61.54 ± 
6.63) 
FH+ showed 
higher FA in the 
corpus callosum 
and superior 
longitudinal 
fasciculus. 
 
No main effect of 
ApoE4 on DTI 
measures. 
 
FH+ApoE4- 
showed lower, 
whereas 
FH+ApoE4+ 
showed higher 
AD in the 
uncinate 
fasciculus. 
Bendlin et 
al. (2010) 
 
* WRAP 
ApoE4 and 
FH  
3T  
DTI 
Cross-sectional: 
TBSS in FSL 
 
FH+ApoE4+: 
n = 35  
(57.5 ± 5.7) 
FH+ApoE4-: 
n = 38  
(57.4 ± 5.4)  
FH-ApoE4+: 
n = 21  
(55.4 ± 5.7)  
FH-ApoE4-: 
n = 42  
(58.4 ± 4.2) 
No effect of 
ApoE4 on DTI 
measures. 
 
FH was 
associated with 
decreased FA in 
widespread AD 
regions. 
 
Additive effects 
of ApoE4 and 
FH resulting in 
lowest FA in 
widespread 
regions including 
the hippocampus. 
Kim et al. 
(2015) 
 
* WRAP 
ApoE4 and 
FH 
3T  
DTI 
Cross-sectional: 
Graph theory 
analyses from 
tractography 
FH+: n = 93  
(62.96 ± 
5.84)  
FH-: n = 250  
(60.29 ± 
6.89) 
FH+ showed 
altered 
connectivity in 
the precuneus. 
Lyall et al. 
(2014) 
 
* Lothian 
Birth Cohort 
1936 
 
ApoE4  
TOMM40 
1.5T  
DTI  
Cross-sectional: 
Tractography in 
FSL 
Total n = 
640-650  
(72.70 ± 
0.74) 
Subgroups 
based on 
ApoE and 
TOMM40 
ApoE4 carriers 
showed mildly 
reductions of FA 
in ventral 
cingulum and the 
inferior 
longitudinal 
fasciculus. 
 
 
Notes: This abbreviated table contains highlighted studies that have more than 30 subjects per 
group, and extra attention was afforded to longitudinal studies. Abbreviations: NS = No 
significant findings; MWF = white matter myelin water fraction; ApoE4 = Apolipoprotein E4; 
WRAP = Wisconsin Registry for Alzheimer Prevention; FH = family history; FA = Fractional 
anisotropy, MD = Mean diffusivity, ROI = Regions of Interest; CTh = Cortical thickness, GM = 
Grey matter; WM = White matter; AAL = Automated Anatomical Labeling, VBM = Voxel 
based morphometry, SPM = Statistical Parametric Mapping. 
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